search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Infection prevention


l Insurance value: helps preserve last line antimicrobials and mitigate catastrophic AMR outbreaks.


l Diversity value: Facilitates more varied and targeted antimicrobial use, reducing resistance selection pressure.


l Enablement value: Allows safe continuation of high-risk medical procedures by ruling in-/ out infections.


l Surveillance value: Enables real-time accurate monitoring of resistance trends.


He argued that healthcare professionals need to ask themselves, ‘What is the value? Why am I doing this test?’ If you are not going to take notice of this and change the management of the patient, based on the results of the test, you probably shouldn’t be performing it,” he commented. He pointed out that 80% of antibiotic


prescriptions are empirical (best guess), and once you start an antibiotic it is difficult to stop it. This is where diagnostics come in – diagnostics need to be able to either rule in or rule out infection – if they are not good at doing either, they are worthless. He added that many (possibly most) clinicians do not truly understand test accuracy – i.e. sensitivity, specificity, positive predictive value and negative predictive value. Some technologies have been withdrawn


from the market after release, due to their “unaffordability”. In contrast, lateral flow tests were cheap and widely used during COVID. Unfortunately, it has been “months or even years” since most people have used a lateral flow test for diagnosing infection, yet they showed the potential to “revolutionise diagnostics”, according to Prof. Wilcox. “We are now trying hard to incentivise companies to produce lateral flow devices that we need today,” he reported. Biomarkers can quickly increase in a patient. Therefore, Prof. Wilcox suggested that performing two tests, after an interval of half an hour, could produce a more accurate result than performing a single test. “You can obtain better information,” he asserted. “This is likely to be the way that we move in the future – towards this biomarker usage,” he commented.


National policy change and targets He reported that the national policy will change going forward – by adding ascertainment measures to infection targets. For example, this will look at the rate of C.diff testing within a Trust – not simply the rates of C.diff recorded. “How can we meaningfully compare how


Trusts are performing if we don’t know how 28 www.clinicalservicesjournal.com I September 2026


‘Piggyback’ infusion


hard they are trying to carry out blood cultures? What is their blood culture sampling rate? These data are already collected but they’ve never been used in anger,” he commented. In the future, the attention will move from


how frequently Trusts are carrying out blood cultures, to looking at how well they are performing those blood cultures. “Are you collecting the right volume of blood


and are you getting those blood cultures into an incubator quickly enough? All those factors affect the chance that the blood cultures will become positive,” Prof. Wilcox explained. He went on to highlight an improvement initiative highlighted at the ECMID conference held in Munich. The Northumbria Healthcare NHS Foundation Trust has optimised the blood culture pathway through a multidisciplinary team collaboration. The programme aimed to increase blood volume per bottle to 8-10mL, reduce collection to incubator time to <4 hours for around 90% of samples and introduce two sets of blood cultures for sepsis patients, as part of a pilot in the critical care unit. Through education, face- to-face reminders, sharing achievements, and understanding the problems and working with the team, the Trust were able to improve the quality of blood cultures. “They increased the blood volume per bottle


from 4 mL to 7.2mL per bottle. Look what happened to the positivity rate of their blood cultures! It went from 9% to 14%, which is a greater than 50% relative increase. How many


patients does that represent who had a positive blood culture that would have been missed by not putting the right amount of blood into the blood culture bottles?” he commented. Initiatives, such as this, demonstrate that


targeting how well blood cultures are taken can have a significant impact, Prof. Wilcox pointed out. There is also now a national blood culture pathway, which aims to drive improvement.2 In conclusion, Prof. Wilcox emphasised that:


l We can prevent more infections; l We can improve outcomes from infection; l We can slow down antibiotic resistance; and l We can get better at diagnosing infection.


Driving improvement in antibiotic delivery In the next session, the attention turned to sustainable IV antibiotic delivery in a presentation titled: ‘Every drop counts’, hosted by B.Braun Medical. Opening the session, Claire Davies, Clinical Therapy Manager (RN), at B. Braun Medical, provided an insight into how under delivery of the full dose occurs. She explained that: l Short-term intermittent infusions are often administered via dedicated pump and/or gravity administration sets.


l The infusion ends but the administration set remains part-filled with air and residual volume of the active drug.


l The administration set is disposed of containing residual volume of the prescribed drug.


“If you are using a 100mL bag, you could be throwing away up to 20% of the patient’s dose, while if you are using a 50mL bag, you could be throwing away as much as 40%,” she commented. She pointed out that antibiotics make up


60% of intermittent infusions e.g., Pip Taz, Co- amoxiclav and Flucloxacillin. “The issue isn’t just about waste; it is about that unintended under-delivery of an antibiotic. Patients may only be receiving 60% of their therapy,” she warned. “The absence of line flushing wasn’t always the case,” she continued pointing out that previous clinical practice included the use of a ‘piggyback’ infusion set. Other countries (e.g, the US) continue to administer antibiotics using piggyback infusions to ensure the full prescribed dose is administered (See left). “This is no longer standard practice in adult nursing in the UK,” she observed. However, there are some exceptions. The total prescribed dose is administered via the flushing of IV giving sets in: l Haematology/Oncology l Paediatrics


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85